Read by QxMD icon Read

Glaucoma and antipsychotics

Elizabeth Shen, Sarah Farukhi, Mason Schmutz, Sameh Mosaed
PURPOSE OF THE STUDY: The purpose of this study was to report a novel case of drug-induced angle-closure from aripiprazole (Abilify), an atypical antipsychotic, and propose a mechanism for this association. METHODS/RESULTS: We report a case of a 45-year-old white woman who presented in subacute angle closure 2 months after initiating aripiprazole 5 mg daily for depression. This patient reported no prior ocular history and had been on longstanding duloxetine (Cymbalta) 60 mg daily for over 10 years before starting aripiprazole...
February 2018: Journal of Glaucoma
Masato Matsuo, Ichiya Sano, Yoshifumi Ikeda, Etsuko Fujihara, Masaki Tanito
OBJECTIVE: We report 3 cases of intraoperative floppy-iris syndrome (IFIS) during cataract surgery in patients without a history of selective α1-blocker use but with a long-term history of antipsychotic drug use. We reviewed previously reported cases of antipsychotic drug-associated IFIS cases. DESIGN: Observational case series. RESULTS: In case 1, bilateral IFIS developed in a 39-year-old man with chronic angle-closure glaucoma. He had used several classes of antipsychotic drugs to treat schizophrenia, including the first-generation antipsychotic drugs haloperidol and chlorpromazine, the dopamine system stabilizer aripiprazole, the dopamine serotonin antagonists olanzapine and quetiapine, and the serotonin dopamine antagonists risperidone and blonanserin for 7 years...
August 2016: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
Po-Han Chou, Che-Sheng Chu, Ching-Heng Lin, Chin Cheng, Yi-Huey Chen, Tsuo-Hung Lan, Min-Wei Huang
OBJECTIVE: Previous research has suggested a link between typical antipsychotic use and the development of cataracts, but the association between atypical antipsychotics and cataracts remains unclear in schizophrenia (SZ). METHODS: A retrospective nested case-control study was conducted using data from the National Health Insurance Database of Taiwan between the year of 2000 and 2011. A total of 2144 SZ patients with cataracts and 2222 controls matched for age, sex, and index date were included...
July 2016: Schizophrenia Research
Badri P Badhu, Balkrishna Bhattarai, Himal P Sangraula
The objective of this study was to review the available literature on the drugs causing ocular hypertension and glaucoma. Electronic literature search was carried out using the Web sites and published through the year 2011. The search words were "drug induced ocular hypertension" and "drug induced glaucoma" used in combination. The articles published or translated into English were studied. Quite a significant number of drugs commonly prescribed by various physicians of different specialties can induce ocular hypertension or glaucoma...
May 2013: Asia-Pacific Journal of Ophthalmology
Malcolm Mitchell, Prajakti Kothare, Richard Bergstrom, Fangyi Zhao, Kai Yu Jen, Daniel Walker, Jason Johnson, David McDonnell
BACKGROUND: This was the first study, to our knowledge, in patients with schizophrenia in which olanzapine long-acting injection (LAI) was used to attempt delivery of depot formulation in multiple therapeutic doses. OBJECTIVE: This study assessed the safety profile, tolerability, and pharmacokinetic (PK) properties of olanzapine after single and multiple administrations of olanzapine LAI and evaluated maintenance of symptom control. METHODS: This was an open-label, multicenter, nonrandomized study of olanzapine LAI in patients with schizophrenia stabilized with oral olanzapine...
December 2013: Clinical Therapeutics
Kaoru Morikawa
The worldwide situations of drug safety have changed dramatically. Drugs are used based on the evaluation of safety data collected in clinical practice worldwide. US Food Drug Administration collects spontaneous reports and requires manufacturers to report adverse drug reactions (ADRs) of US marketed drugs occurring worldwide. These worldwide data are available through the Adverse Event Reporting System (AERS) (about 4.1 million reports on about 3,073,340 patients, for 13 years: 1997.4th qr-2010.4th qr.). The current issues are how to analyze and utilize such large-scale safety data...
2011: Kokuritsu Iyakuhin Shokuhin Eisei Kenkyūjo Hōkoku, Bulletin of National Institute of Health Sciences
Sumalee Boonyaleephan
Several classes of drugs have potential to cause an elevation of IOP which may occur either by an open-angle mechanism or a close-angle mechanism. Drug-induced elevation of IOP is commonly has an open-angle mechanism. The most commonly recognized medications associated with this mechanism are the corticosteroids. Acute angle closure glaucoma is a potentially blinding side effect of local and systemic drugs, including antipsychotic drugs, antidepressants, monoamine oxidase inhibitors, antihistamines, antiparkinsonian agents, antispasmolytic drugs, mydriatic agents, the sympathetic agents and botulinum toxin, especially in individuals with predisposing narrow angles of the anterior chamber...
February 2010: Journal of the Medical Association of Thailand, Chotmaihet Thangphaet
Káthia M Honório, Emmanuela F de Lima, Marcos G Quiles, Roseli A F Romero, Fábio A Molfetta, Albérico B F da Silva
Cannabinoid compounds have widely been employed because of its medicinal and psychotropic properties. These compounds are isolated from Cannabis sativa (or marijuana) and are used in several medical treatments, such as glaucoma, nausea associated to chemotherapy, pain and many other situations. More recently, its use as appetite stimulant has been indicated in patients with cachexia or AIDS. In this work, the influence of several molecular descriptors on the psychoactivity of 50 cannabinoid compounds is analyzed aiming one obtain a model able to predict the psychoactivity of new cannabinoids...
June 2010: Chemical Biology & Drug Design
Sami Richa, Jean-Claude Yazbek
All psychotropic medications have the potential to induce numerous and diverse unwanted ocular effects. Visual adverse effects can be divided into seven major categories: eyelid and keratoconjunctival disorders; uveal tract disorders; accommodation interference; angle-closure glaucoma; cataract/pigmentary deposits in the lens and cornea; retinopathy; and other disorders. The disorders of the eyelid and of the keratoconjunctiva are mainly related to phenothiazines and lithium. Chlorpromazine, at high dosages, can commonly cause abnormal pigmentation of the eyelids, interpalpebral conjunctiva and cornea...
June 2010: CNS Drugs
Mohammad Reza Razeghinejad, Mohammad Hosein Nowroozzadeh, Mohammad Zamani, Nima Amini
Chlorpromazine is known to deposit in ocular tissues when taken at high doses for prolonged periods. Chlorpromazine therapy in a 59-year-old schizophrenic man with a cumulative dosage exceeding 2500 g resulted in multiple white deposits in both corneas especially in the endothelium. Confocal microscopy revealed significant pleomorphism and polymegethism of endothelial cells. The anterior lens capsules opacities were star-shaped and concentrated in the centre. Because of cataract and chronic angle closure glaucoma our high-myopic patient underwent surgery, and light microscopic evaluation of the obtained anterior lens capsule during cataract surgery showed golden brown cytoplasmic deposits in the central epithelial cells and capsule...
August 2008: Clinical & Experimental Ophthalmology
Junping Li, Ramesh C Tripathi, Brenda J Tripathi
While beneficial therapeutically, almost all medications have untoward effects on various body tissues and functions, including the eye in which organ toxic reactions are readily detectable. Every part of the eye and all ocular functions could be affected adversely. In this review, we describe the most commonly recognized drug-induced ocular disorders, their specific clinical features, the medications that can cause the problem, the differential diagnosis and possible mechanisms of action, as well as guidelines for the management of the adverse reactions...
2008: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
Barry W Rovner
PURPOSE OF REVIEW: The Charles Bonnet syndrome is a disorder of visual hallucinations typically occurring in older persons with vision impairment or deafferentation of the visual cortex. This review cites recent studies on Charles Bonnet syndrome and discusses treatment options. The numbers of affected persons will increase with aging of the population, making recognition and treatment important components of ophthalmologic care. RECENT FINDINGS: The etiology of the Charles Bonnet syndrome is varied; most often it involves direct damage to the visual system (e...
June 2006: Current Opinion in Ophthalmology
Rita Moretti, Paola Torre, Rodolfo M Antonello, Giuseppe Cazzato, Antonio Bava
BACKGROUND: Although the core feature of dementia is progressive cognitive disruption, non-cognitive behavioural problems are expressed in most patients with dementia during the course of their illness. While psychotropic drugs are frequently used to control behavioural symptoms, comorbidities, which are very common in the geriatric population, could often limit their use. Gabapentin may be a potential treatment in such situations. METHODS: In this open, baseline comparison study 20 patients with probable Alzheimer's disease with behavioural alterations and serious comorbidities (paralytic ileus, open-angle glaucoma, ischaemic cardiopathy, hepatic failure or severe prostatic hyperplasia) received gabapentin for 15 months...
2003: Drugs & Aging
Sean Hennessy, Warren B Bilker, Jill S Knauss, David J Margolis, Stephen E Kimmel, Robert F Reynolds, Dale B Glasser, Mary F Morrison, Brian L Strom
OBJECTIVE: To examine the rates of cardiac arrest and ventricular arrhythmia in patients with treated schizophrenia and in non-schizophrenic controls. DESIGN: Cohort study of outpatients using administrative data. SETTING: 3 US Medicaid programmes. PARTICIPANTS: Patients with schizophrenia treated with clozapine, haloperidol, risperidone, or thioridazine; a control group of patients with glaucoma; and a control group of patients with psoriasis...
November 9, 2002: BMJ: British Medical Journal
Jeffrey Berlant, Daniel P van Kammen
BACKGROUND: The hypothesis that exposure to traumatic events may sensitize or kindle limbic nuclei has led to efforts to treat posttraumatic stress disorder (PTSD) with anticonvulsants. Based on the kindling hypothesis of PTSD, this open-label study assesses clinical response to topiramate as a potential treatment for DSM-IV PTSD. METHOD: A naturalistic data review was conducted of medical records of all adult outpatients (9 men. 26 women symptomatic for a mean +/- SD of 18 +/- 15 years with DSM-IV chronic civilian PTSD) treated with topiramate, 12...
January 2002: Journal of Clinical Psychiatry
E Pop
Dexanabinol is a non-psychotropic cannabinoid NMDA receptor antagonist under development by Pharmos Corp for the potential treatment of cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury and multiple sclerosis (MS) [311522]; it is in phase III trials for traumatic brain injury (TBI) [388709]. Dexanabinol was licensed to Pharmos for development from its originator, the Hebrew University of Jerusalem [180441]. Pharmos is seeking to enter into a strategic agreement with another company to develop and commercialize dexanabinol [317369]...
December 2000: Current Opinion in Investigational Drugs
T Oshika
Neuropsychiatric agents may adversely affect the eye in various ways. The more frequently encountered effects include corneal oedema and pigmentary changes in the lens and cornea which are induced by phenothiazine derivatives; thioridazine-induced retinopathy; tricyclic antidepressant-induced accommodation interference and glaucoma; and lithium carbonate-induced exophthalmos and papilloedema. Several adverse effects, such as corneal oedema, retinopathy and glaucoma, are vision-threatening, and patients often fail to describe their symptoms properly...
April 1995: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
G C Chiou
Haloperidol, a dopaminergic antagonist, was found to be very effective in suppressing the intraocular pressure recovery curve of rabbits infused with 20% saline intravenously. Haloperidol was at least equipotent, if not more potent, in lowering IOP and had much longer duration of action compared with timolol maleate. In the cat model, haloperidol increased aqueous humor (AH) outflow initially, followed by a long-lasting suppression of AH formation. Since haloperidol does not block beta-adrenergic receptors and the ophthalmic dose required to lower IOP is only 6...
January 1984: Archives of Ophthalmology
G C Chiou
A group of dopamine antagonists have been studied for their ability to suppress the intraocular pressure (IOP) recovery rate of rabbits infused with hypertonic saline. All dopamine antagonists examined were either equipotent or more potent than beta-adrenergic blocker, timolol, to lower the IOP in the following order: haloperidol greater than moperone = trifluperidol greater than clofluperol = pipamperone = lenperone = timolol. Contrary to timolol, haloperidol, moperone and trifluperidol relaxed histamine pretreated guinea pig tracheal muscle at doses as low as 0...
1984: Ophthalmic Research
D Bandych-Biniszkiewiczowa
No abstract text is available yet for this article.
July 1983: Klinika Oczna
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"